In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Scholar Rock Holding, with a price target of $44.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Scholar Rock Holding’s promising future. The company is making significant progress in advancing its lead SMA program, particularly with the constructive dialogue with the FDA, which supports its plan for a BLA resubmission in 2026. Scholar Rock’s strategic decision to contract an additional US fill-finish facility with a strong regulatory track record aims to accelerate timelines for a potential US launch, demonstrating their commitment to overcoming previous hurdles.
Furthermore, the company’s commercial readiness efforts are robust, with expanded engagement across numerous SMA centers and prescribers, which strengthens their market position. Scholar Rock’s apitegromab, with its unique mechanism that complements existing therapies, positions it as a pioneering muscle-directed therapy for SMA. The ongoing remediation efforts and the FDA’s lack of clinical concerns reinforce the belief in apitegromab’s potential, supporting the Buy rating with a $44 price target.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRRK in relation to earlier this year.